VAI TRÒ CỦA APOE ε4 VÀ BIOMARKER TRONG ĐIỀU TRỊ BỆNH ALZHEIMER THEO CƠ CHẾ THAY ĐỔI BỆNH

Abstract

Among the causes of dementia, Alzheimer's disease is the most common cause, accounting for 60-70%. In the past 20 years, many genetic tests and biomarkers have been developed to help early diagnosis and treatment of diseases. The test helps provide pathological evidence of Alzheimer's disease, helping to diagnose the disease in the preclinical stage. As disease-modifying treatments for Alzheimer's disease begin to develop, biomarker testing becomes increasingly important in identifying patients for treatment. In particular, the development of genetic testing and serum biomarkers (APOE gene, amyloid-β Aβ42/Aβ40, t-tau, p-tau181, p-tau217) allows easy and accurate testing on patients. core. In the future, there will be more and more biomarker tests that will help with early diagnosis, thereby selecting appropriate treatment subjects as well as monitoring and predicting drug treatment based on disease-modifying mechanisms.